Choe J, Lee S, Ahn J, Lee H, Oh J, Choi J
J Clin Med. 2023; 12(18).
PMID: 37763042
PMC: 10532039.
DOI: 10.3390/jcm12186099.
Dabhi K, Gohil N, Tanveer N, Hussein S, Pingili S, Makkena V
Cureus. 2023; 15(7):e42029.
PMID: 37465091
PMC: 10351747.
DOI: 10.7759/cureus.42029.
Bonilha I, Hajduch E, Luchiari B, Nadruz W, Le Goff W, Sposito A
Metabolites. 2021; 11(12).
PMID: 34940565
PMC: 8708656.
DOI: 10.3390/metabo11120807.
Alam U, Al-Bazz D, Soran H
Diabetes Ther. 2021; 12(7):1779-1789.
PMID: 34037950
PMC: 8266948.
DOI: 10.1007/s13300-021-01070-6.
Rath A, Lam H, Schooling C
Eur J Clin Nutr. 2021; 75(11):1668-1678.
PMID: 33828238
DOI: 10.1038/s41430-021-00882-w.
Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence.
Camerino G, Tarantino N, Canfora I, De Bellis M, Musumeci O, Pierno S
Int J Mol Sci. 2021; 22(4).
PMID: 33669797
PMC: 7921957.
DOI: 10.3390/ijms22042070.
Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy.
Urbano F, Di Pino A, Scicali R, Filippello A, Di Mauro S, Scamporrino A
Eur J Endocrinol. 2019; 181(6):579-590.
PMID: 31546230
PMC: 6977939.
DOI: 10.1530/EJE-19-0173.
Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes.
Sunjaya A, Sunjaya A, Halim S, Ferdinal F
Int J Angiol. 2018; 27(3):121-131.
PMID: 30154630
PMC: 6103774.
DOI: 10.1055/s-0036-1572523.
Short‑term use of atorvastatin affects glucose homeostasis and suppresses the expression of LDL receptors in the pancreas of mice.
Yu Q, Wang F, Meng X, Gong Y, Wang Y, Xu C
Mol Med Rep. 2018; 18(3):2780-2788.
PMID: 30015940
PMC: 6102652.
DOI: 10.3892/mmr.2018.9239.
Statin on insulin and adiponectin levels: true or false prophecy?.
Jonnalagadda V, Shaik A
Diabetes Metab Syndr Obes. 2018; 11:131.
PMID: 29697702
PMC: 5905842.
DOI: 10.2147/DMSO.S160853.
Risk of new-onset diabetes among patients treated with statins according to hypertension and gender: Results from a nationwide health-screening cohort.
Lee S, Sung J, Cho I, Kim H, Chang H
PLoS One. 2018; 13(4):e0195459.
PMID: 29630642
PMC: 5891021.
DOI: 10.1371/journal.pone.0195459.
Statins and New-Onset Diabetes Mellitus: LDL Receptor May Provide a Key Link.
Yu Q, Chen Y, Xu C
Front Pharmacol. 2017; 8:372.
PMID: 28659805
PMC: 5468445.
DOI: 10.3389/fphar.2017.00372.
The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature.
Diamantis E, Kyriakos G, Quiles-Sanchez L, Farmaki P, Troupis T
Curr Cardiol Rev. 2017; 13(3):209-216.
PMID: 28462692
PMC: 5633715.
DOI: 10.2174/1573403X13666170426104611.
THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW.
Grodzinsky A, Arnold S, Jacob D, Draznin B, Kosiborod M
Endocr Pract. 2016; 23(3):363-371.
PMID: 27967225
PMC: 5828513.
DOI: 10.4158/EP161309.RA.
Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study.
Millan Nunez-Cortes J, Cases Amenos A, Ascaso Gimilio J, Barrios Alonso V, Fuster V, Pedro-Botet Montoya J
Am J Cardiovasc Drugs. 2016; 17(2):135-142.
PMID: 27837448
PMC: 5340834.
DOI: 10.1007/s40256-016-0197-9.
Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (from the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trials).
Kohli P, Knowles J, Sarraju A, Waters D, Reaven G
Am J Cardiol. 2016; 118(9):1275-1281.
PMID: 27614854
PMC: 6686184.
DOI: 10.1016/j.amjcard.2016.07.054.
Long-Term Outcomes of Short-Term Statin Use in Healthy Adults: A Retrospective Cohort Study.
Mansi I, English J, Zhang S, Mortensen E, Halm E
Drug Saf. 2016; 39(6):543-59.
PMID: 26979831
DOI: 10.1007/s40264-016-0412-2.
The diabetogenic action of statins - mechanisms and clinical implications.
Betteridge D, Carmena R
Nat Rev Endocrinol. 2015; 12(2):99-110.
PMID: 26668119
DOI: 10.1038/nrendo.2015.194.
Different effects of statins on induction of diabetes mellitus: an experimental study.
Zhao W, Zhao S
Drug Des Devel Ther. 2015; 9:6211-23.
PMID: 26648697
PMC: 4664500.
DOI: 10.2147/DDDT.S87979.
Statin-activated nuclear receptor PXR promotes SGK2 dephosphorylation by scaffolding PP2C to induce hepatic gluconeogenesis.
Gotoh S, Negishi M
Sci Rep. 2015; 5:14076.
PMID: 26392083
PMC: 4585725.
DOI: 10.1038/srep14076.